For the fiscal quarter ending June 30, 2026, Neuroone Medical Technologies is expected to report a consensus loss of $0.22 per share on revenue of $2.5 million, with its $1.63 stock price trading at a steep discount to the $9.93 average analyst price target.
The primary focus for investors this quarter is the commercial ramp and procedural volume of the OneRF ablation system following its recent application in trigeminal neuralgia treatments.
The company demonstrated strong momentum with a 72% revenue increase in the previous quarter, though it remains in an early commercialization phase with significant research and development outlays. Management’s ability to secure ISO 13485 certification and finalize international distribution agreements is considered essential for sustaining its current growth trajectory.